November 01, 2017 – According to the watch list of the American Food & Drug Administration (FDA) for drugs with possible safety issues from January to March 2016, the FDA was looking at the possible link between various drugs in the phosphodiesterase-5 …

Is there a risk of melanoma with erectile dysfunction drugs? Read more »

Tagged with: , , , , , , , , , , , , , , ,

August 26, 2017 – The erectile dysfunction (ED) drugs Tadalafil (Cialis), Vardenafil (Levitra), and even more so Sildenafil (Viagra) have previously been associated with a type of sudden vision loss called Nonarteritic Anterior Ischemic Optic Neuropathy (NAION). According to a recent …

Happy but blind: A role for erectile dysfunction (ED) drugs Read more »

Tagged with: , , , , , ,

September 22, 2016 – The pharmacologically active compound known as sildenafil is largely used to treat erectile dysfunction (on the market for this indication under the trade name Viagra) and pulmonary arterial hypertension (on the market for this indication under the trade name Revatio) in …

Granpidam: A generic to Sildenafil (Revatio) Read more »

Tagged with: , , , , , , , , , ,

November 25, 2015 – Right in time for the upcoming holyday season, this post addresses once more the issue of tainted sexual enhancement products. Such products, bought over the counter (OTC) or from Internet stores may pose serious health risks …

Stiff Nights: Dangerously tainted sexual enhancement products are everywhere Read more »

Tagged with: , , , , , , , , ,

Flibanserin (ADDYI)

June 5, 2015 – This is an edited post based on a PRNewswire release (see here) which refers to the 2015 June 4th joint meeting of  the U.S. Food and Drug Administration’s (FDA) joint meeting of the Bone, Reproductive and Urologic Drugs Advisory …

The “female” Viagra: Will it one day be a commercial success? Approval recommended for Flibanserin (ADDYI) to treat hypoactive sexual desire disorder (HSDD) in premenopausal women Read more »

Tagged with: , , , , ,

March 31, 2014 –  The American Food and Drug Administration (FDA) is clarifying its previous recommendation related to prescribing Sidenafil [Revatio] for children with pulmonary arterial hypertension (PAH). Note that the pharmacologically active compound sildenafil is also the pharmacologically active …

Sildenafil [Revatio]: FDA Clarifies Warning About Pediatric Use for Pulmonary Arterial Hypertension (PAH) Read more »

Tagged with: , , , , , ,